Home - Products - Angiogenesis - FLT - TG-89

TG-89

CAS No. 936091-56-4

TG-89( —— )

Catalog No. M33687 CAS No. 936091-56-4

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	85	Get Quote
5MG	149	Get Quote
10MG	237	Get Quote
25MG	382	Get Quote
50MG	544	Get Quote
100MG	718	Get Quote
500MG	1431	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

TG-89
Note

Research use only, not for human use.
Brief Description

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
Description

JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

FLT
Recptor

FLT | JAK | c-RET
Research Area

——
Indication

——

Chemical Information

CAS Number

936091-56-4
Formula Weight

510.65
Molecular Formula

C26H34N6O3S
Purity

>98% (HPLC)
Solubility

——
SMILES

Cc1cnc(Nc2cccc(CN3CCOCC3)c2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Glenn Noronha, et al. Bi-aryl meta-pyrimidine inhibitors of kinases. Patent. US20110212077A1.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

JI6

JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
Merestinib dihydroch...

Merestinib dihydrochloride (LY2801653 dihydrochloride) is an orally available kinase inhibitor with antitumor activity that inhibits MET, AXL, RON, and MKNK1/2, and inhibits the growth of NTRK fusion-carrying tumors.
Emavusertib

Emavusertib is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.

Sign In Join Free